Diphenyl Derivatives with Sulfooxy Groups for Reduced Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional triazene cytostatics suffer from severe side effects such as bone marrow depression, neurotoxicity, and liver toxicity, limiting their long-term use in cancer treatment, despite their cytostatic effectiveness.
Innovation Solution
Development of new diphenyl derivatives containing a dialkyltriazenyl group and a sulfooxy or sulfamoyloxy group, which exhibit improved antitumor effects with reduced toxic side effects, making them suitable for long-term therapy as monotherapy or in combination with other carcinostatics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional triazene cytostatics are used for cancer treatment, then cytostatic effectiveness is achieved, but severe toxic side effects occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of triazene compounds through the introduction of specific substituent groups (sulfooxy and sulfamoyloxy groups) at defined positions on the diphenyl framework. This structural modification changes the pharmacological parameters of the compound, resulting in reduced toxicity while maintaining or enhancing cytostatic effectiveness. The systematic variation of substituent types and their positions represents a classic parameter change approach to resolving the contradiction between efficacy and toxicity.
2Reliability
If conventional triazene cytostatics are used, then antitumor activity is achieved, but long-term use is limited due to severe side effects
Solution Approach 1:
The patent employs parameter changes by systematically modifying the chemical parameters of triazene compounds through the introduction of sulfooxy and sulfamoyloxy substituent groups. These structural parameter changes result in compounds with improved pharmacological profiles that allow for extended therapy duration. The modified compounds maintain antitumor activity while reducing cumulative toxicity, thereby enabling long-term treatment regimens that were not feasible with conventional triazenes.
3Reliability
If dacarbazine and temozolomide are used for glioblastoma treatment, then treatment effectiveness is achieved, but considerable side effects occur including bone marrow depression and neurotoxicity
Solution Approach 1:
The patent applies the local quality principle by introducing specific functional groups (sulfooxy and sulfamoyloxy) at particular positions on the diphenyl ring system. This localized modification of the molecular structure creates regions with different chemical and biological properties. The strategically placed substituents modify the compound's interaction with biological targets and metabolic pathways, thereby reducing specific toxic effects such as bone marrow depression and neurotoxicity while preserving the core antitumor activity.
Solution Approach 2:
The patent utilizes parameter changes by systematically varying the chemical structure of triazene compounds through the introduction of sulfooxy and sulfamoyloxy groups at defined positions. This structural parameter modification alters the pharmacological profile of the compounds, resulting in reduced toxicity to specific organs (bone marrow, nervous system) while maintaining effectiveness against glioblastoma. The parameter changes enable differentiation between therapeutic effect and toxic side effects.
Data Source
AI summary
Triazene-substituted diphenyl derivatives are suitable as chemotherapeutic agents for treating carcinomas in humans and animals.